{"id":"W4390902638","doi":"10.1200/jco.23.01569","title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Western University; Juravinski Cancer Centre","funders":"Cilag; EMD Serono; Genentech; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; Chugai Pharmaceutical; AstraZeneca; EUSA Pharma; Seagen; LG Chem; Advanced Accelerator Applications; Pfizer; Incyte; Ipsen; BeiGene; Tizona Therapeutics; Sanofi; Exelixis; Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Lenvatinib; Sunitinib; Clinical endpoint; Renal cell carcinoma; Internal medicine; Hazard ratio; Pembrolizumab; Discontinuation; Oncology; Phases of clinical research; Clinical trial; Confidence interval; Cancer; Sorafenib; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001983344,0.0003739155,0.004376182,0.001062416,0.00003280209,0.00001134757,0.0002404536,0.0003349466,0.0003866599],"category_scores_gemma":[0.0007314513,0.0002682325,0.001693175,0.0009692255,0.0002282133,0.00012608,0.00007528141,0.0007490755,0.000005018711],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0010007,"about_ca_system_score_gemma":0.002391688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003864515,"about_ca_topic_score_gemma":0.001093593,"domain_scores_codex":[0.9925085,0.0008384227,0.004907202,0.000495869,0.0008570024,0.0003929488],"domain_scores_gemma":[0.9908697,0.005664904,0.002024238,0.0005070361,0.0005363981,0.0003977398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7115575,0.07573561,0.06760972,0.0003504159,0.01436036,0.02180202,0.004700905,0.009288128,0.001583721,0.0001281637,0.0003478717,0.09253556],"study_design_scores_gemma":[0.2779063,0.3048626,0.3911444,0.0001609765,0.01502938,0.00009039714,0.001314592,0.003104469,0.001561147,0.00003052175,0.004536364,0.000258863],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926637,0.002036301,0.00003865078,0.000517327,0.001004261,0.0008213614,0.00004869591,0.00001212049,0.002857615],"genre_scores_gemma":[0.9974073,0.0007876407,0.0006473955,0.00002627061,0.0005062063,0.00002105402,0.00003757253,0.00003566237,0.0005308752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4336513,"threshold_uncertainty_score":0.999977,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2490517273837873,"score_gpt":0.4762400422636671,"score_spread":0.2271883148798799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}